3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
21
Neurofibromatosis 1
19
Melanoma
11
Neurofibroma, Plexiform
10
Lung Neoplasms
8
Neoplasms
7
Neoplasm Metastasis
7
Colorectal Neoplasms
7
Breast Neoplasms
7
Solid Tumours
5
Pancreatic Neoplasms
4
Carcinoma, Hepatocellular
4
Uveal Melanoma
3
Triple Negative Breast Neoplasms
3
Thyroid Neoplasms
3
Rectal Neoplasms
3
Neurofibrosarcoma
3
Gallbladder Neoplasms
3
Colonic Neoplasms
3
Biliary Tract Neoplasms
3
Thyroid Cancer, Papillary
2
Sarcoma
2
Bile Duct Neoplasms
2
Adult Solid Neoplasm
2
Thyroid Diseases
1
Thymoma
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma, Kaposi
1
Renal Insufficiency
1
Interventions
tislelizumab
2
Cystectomy
2
vistusertib
1
toripalimab
1
olaparib
1
liposomal doxorubicin
1
durvalumab
1
disitamab vedotin
1
danvatirsen
1
adavosertib
1
Surgical Procedures, Operative
1
Rutin
1
Radiation
1
RC48 antibody
1
Neoadjuvant Therapy
1
Gemcitabine
1
Cisplatin
1
Chemoradiotherapy
1
AZD4547
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Muscle Invasive Bladder Cancer
×
AZD 6244
×
Clear all
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled